secwatch.observer — SEC 8-K summary
======================================

Issuer:     AVITA Medical, Inc. (RCEL)
CIK:        0001762303
Form:       8-K
Filed at:   2024-08-08T23:59:59+00:00
Accession:  0000950170-24-093941
Event type: earnings
Sentiment:  positive
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

AVITA Medical Q2 commercial revenue record $15.1M (+29%); FY24 guide $68-70M
----------------------------------------------------------------------------

- Commercial revenue $15.1M (+29% YoY); gross margin 86.2% (up 500 bps).
- Net loss $15.4M ($0.60 loss per share) vs $10.4M loss ($0.41) in Q2 2023.
- RECELL GO PMA approved May 29; RECELL GO mini submitted June 28, FDA decision by Dec 27.
- Exclusive distribution deal with Regenity for dermal matrix; 510(k) clearance expected Q4 2024.
- Q3 2024 revenue guidance $19-20M (40-48% YoY growth); FY24 guide revised to $68-70M (37-41% growth).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1762303/000095017024093941/0000950170-24-093941-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1762303/000095017024093941/rcel-20240808.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-093941

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer